SARS Envelope Antibody |
24321-100ul |
SAB |
100ul |
EUR 468 |
Human IgG antibody Laboratories manufactures the sars-cov2 envelope proteine mybiosource reagents distributed by Genprice. The Sars-Cov2 Envelope Proteine Mybiosource reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Mybiosource. Other Sars-Cov2 products are available in stock. Specificity: Sars-Cov2 Category: Envelope Group: Proteine Mybiosource
SARS Envelope Antibody |
SAB |
100ul |
EUR 468 |
SARS Envelope Antibody |
SAB |
100ul |
EUR 468 |
Proteine Mybiosource information
Recombinant Coronavirus Envelope Protein (SARS-CoV) |
P1534-50 |
Biovision |
50 µg |
EUR 661.2 |
SARS-CoV Envelope Antibody |
3533-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS-CoV Envelope Antibody |
3533-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS Coronavirus Envelope Recombinant Protein |
39-104 |
ProSci |
0.05 mg |
EUR 556.8 |
Description: SARS Associated Coronavirus Envelope is a small membrane protein that takes major part in the life cycle of the virus. This protein is needed for the assembly, budding, creation of the envelope and pathogenesis. This protein contains 3 outer structural proteins, the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to assure viral entry thetarget cells. Accordingly, S-protein has a major part in virus infection cycle and is the mainly target of neutralizing antibodies. |
SARS Coronavirus Envelope Recombinant Protein |
39-118 |
ProSci |
0.1 mg |
EUR 556.8 |
Description: SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
Recombinant Coronavirus Envelope Protein (SARS-CoV ENV;1-76) |
P1503-10 |
Biovision |
10µg |
EUR 187.2 |
Recombinant Coronavirus Envelope Protein (SARS-CoV ENV;1-76) |
P1503-50 |
Biovision |
50µg |
EUR 661.2 |
Recombinant SARS-CoV-2 envelope Protein with His and Avi Tag |
E80005-1 |
EpiGentek |
100 ul |
EUR 518.1 |
SARS Coronavirus Envelope (HSZ-Cc) Recombinant Protein |
20-197 |
ProSci |
0.1 mg |
EUR 726.9 |
Description: SARS Coronavirus Envelope (HSZ-Cc) Recombinant Protein |
SARS Coronavirus Envelope (HSZ-Cc) Recombinant Protein |
20-222 |
ProSci |
0.1 mg |
EUR 726.9 |
Description: SARS Coronavirus Envelope (HSZ-Cc) Recombinant Protein |
Recombinant SARS Associated Coronavirus Envelope |
7-07117 |
CHI Scientific |
100µg |
Ask for price |
Recombinant SARS Associated Coronavirus Envelope |
7-07118 |
CHI Scientific |
500µg |
Ask for price |
Recombinant SARS Associated Coronavirus Envelope |
7-07119 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant (E.Coli) SARS Associated Coronavirus Envelope |
RP-1418 |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
HIV 2 Envelope Protein |
abx060590-1mg |
Abbexa |
1 mg |
EUR 1888.8 |
|
HIV-2 Envelope Protein |
20-abx260147 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|